Wilex AG

Wilex AG, a biopharmaceutical company, focuses on the development of cancer therapies based on antibodies and small molecules. Its compounds under clinical development include WX-G250 (RENCAREX), WX-671, WX-UK1, CA9-SCAN, and WX-77x. The company’s WX-G250 (RENCAREX) is in Phase III registration ARISER trial as an antibody for the therapy of non-metastatic clear cell renal cell carcinoma; and WX-671 is a Phase II clinical trial candidate for the treatment of pancreatic cancer. Its WX-UK1, a serine protease inhibitor, is in Phase II clinical trail for the treatment of solid cancers; CA9-SCAN, an antibody-based radiopharmaceutical to support physicians in diagnosing renal cancers, is in Phase III registration trial; and WX-77x, an oral protease inhibitor for the treatment of cancer, is in preclinical stage. Wilex AG was founded in 1997 and is based in Munich, Germany.